Open AccessThe Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial
Author(s) -
Xianmixikemaier Abulizi,
Heather J. Ribaudo,
Philippe Flandre
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001978
Subject(s) - equivalence (formal languages) , hazard ratio , clinical trial , human immunodeficiency virus (hiv) , survival analysis , medicine , statistics , mathematics , confidence interval , family medicine , discrete mathematics
The restricted mean survival time (RMST) measures have not been used as primary measure of efficacy in HIV/AIDS clinical trials. In this work, we aim to compare analysis based on the difference in RMST (Δ-RMST) measure and 2 other treatment-effect measures in a recent HIV equivalence trial, and to investigate the performance and characteristics of Δ-RMST-based analysis in a simulation study.